Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

被引：13

作者：

Zaja, Francesco ^{[1
,2
]}

Salvi, Flavia ^{[3
]}

Rossi, Maura ^{[4
]}

Sabattini, Elena ^{[5
]}

Evangelista, Andrea ^{[5
]}

Ciccone, Giovannino ^{[6
,7
]}

Angelucci, Emanuele ^{[8
]}

Gaidano, Gianluca ^{[9
]}

Zanni, Manuela ^{[9
]}

Ladetto, Marco ^{[3
]}

Chiappella, Annalisa ^{[10
]}

Vitolo, Umberto ^{[10
]}

Zinzani, Pier Luigi ^{[11
]}

Califano, Catello ^{[12
]}

Tucci, Alessandra ^{[13
,14
]}

Patti, Caterina ^{[15
]}

Pileri, Stefano A. ^{[16
]}

Lenti, Valentina ^{[17
]}

Piccaluga, Pier Paolo ^{[4
]}

Cavallo, Federica ^{[18
]}

Volpetti, Stefano ^{[19
,20
]}

Perali, Giulia ^{[19
,20
]}

Assouline, Sarit ^{[21
]}

Mann, Koren Kathleen ^{[22
]}

Morin, Ryan ^{[23
]}

Alcaide, Miguel ^{[23
]}

Bushell, Kevin ^{[23
]}

Fanin, Renato ^{[1
,2
]}

Levis, Alessandro ^{[17
]}

机构：

[1] Univ Udine, Clin Ematol, DAME, Udine, Italy

[2] Univ Udine, Unita Terapie Cellulari Carlo Melzi, DAME, Udine, Italy

[3] AO SS Antonio & Biagio & C Arrigo, SC Ematol, Alessandria, Italy

[4] Univ Hosp Bologna, Unit Haemolymphopathol, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[5] Univ Hosp Bologna, Dept Hematol & Oncol, Unit Haemolymphopathol, Bologna, Italy

[6] AOU Citta Salute & Sci Torino, Unit Clin Epidemiol, Turin, Italy

[7] CPO Piemonte, Turin, Italy

[8] IRCCS AOU San Martino IST, UOC Ematol, Genoa, Italy

[9] Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Div Hematol, Novara, Italy

[10] AOU Citta Salute & Sci, SC Ematol, Turin, Italy

[11] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy

[12] Osped Umberto I, UO Med Oncoematol, Nocera Inferiore, Italy

[13] Spedali Civil Brescia, SC Ematol, Brescia, Italy

[14] Spedali Civil Brescia, Dipartimento Oncol Med, Brescia, Italy

[15] Osped V Cervello, UOC Ematol, Palermo, Italy

[16] Milano Univ, Sch Med, European Inst Oncol, Haematopathol Unit, Bologna, Italy

[17] Fdn Italiana Linfomi, Alessandria, Italy

[18] Univ Torino, Azienda Osped Univ Citta Salute & Sci, Turin, Italy

[19] Azienda Sanit Univ Integrata, Clin Ematol, Udine, Italy

[20] Azienda Sanit Univ Integrata, Unita Terapie Cellulari Carlo Melzi, Udine, Italy

[21] McGill Univ, Jewish Gen Hosp, Div Hematol, Montreal, PQ, Canada

[22] McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada

[23] Simon Fraser Univ, Dept Mol Biol & Biochem, Sch Comp Sci, Vancouver, BC, Canada

来源：

LEUKEMIA & LYMPHOMA | 2018年 / 59卷 / 12期

关键词：

Diffuse large B-cell lymphoma; panobinostat; relapsed/refractory; genomic; DEACETYLASE INHIBITOR PANOBINOSTAT; HISTONE DEACETYLASES; RITUXIMAB; DISEASE; MULTICENTER; ROMIDEPSIN; MUTATION; LBH589; TRIAL; CHOP;

D O I：

10.1080/10428194.2018.1452208

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We investigated panobinostat 40 mg three times weekly in 35 adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Overall response rate and complete response were 17.1% and 11.4%, respectively. Median progression-free survival (PFS) and overall survival were 2.4 and 7.6 months, respectively. Calculated 12, 24 and 36 months PFS were 26%, 11% and 11%, respectively. Four patients who achieved a sustained CR, continued receiving panobinostat for an overall period of 44, 48, 50, 62 months. Thrombocytopenia grade 3 (5 patients) and 4 (24 patients) represented the main toxic effect, causing dose reduction or treatment suspension in 19 patients. Genomic analysis was unable to identify any relationship between mutations and response; TP53 mutation appeared not to impact the clinical outcome. Overall, panobinostat has a modest activity in R/R DLBCL patients, however it can induce very long lasting responses in some cases. Thrombocytopenia frequently limits the use of this agent.

引用

页码：2904 / 2910

页数：7

共 50 条

[1] Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Islam, Prioty
Rizzieri, David
Lin, Chenyu
de Castro, Carlos
Diehl, Louis
Li, Zhiguo
Moore, Joseph
Morris, Tod
Beaven, Anne
CANCER INVESTIGATION, 2021, 39 (10) : 871 - 879
[2] Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi
Merli, Francesco
Cavallo, Federica
Salvi, Flavia
Tucci, Alessandra
Musuraca, Gerardo
Nassi, Luca
Merli, Michele
Tani, Monica
Gini, Guido
Ferrari, Angela
Molinari, Anna Lia
Liberati, Anna Marina
Conconi, Annarita
Matteucci, Paola
Bari, Alessia
Scalone, Renato
Ferrero, Simone
Zanni, Manuela
Mammi, Caterina
Luminari, Stefano
JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (01) : 37 - 40
[3] Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi
Merli, Francesco
Luminari, Stefano
Rossi, Giuseppe
Mammi, Caterina
Marcheselli, Luigi
Ferrari, Angela
Spina, Michele
Tucci, Alessandra
Stelitano, Caterina
Capodanno, Isabella
Fragasso, Alberto
Baldini, Luca
Bottelli, Chiara
Montechiarello, Elisa
Fogazzi, Stefano
Lamorgese, Cinzia
Cavalli, Lara
Federico, Massimo
LEUKEMIA & LYMPHOMA, 2014, 55 (01) : 38 - 43
[4] Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi
Merli, Francesco
Luminari, Stefano
Tucci, Alessandra
Arcari, Annalisa
Rigacci, Luigi
Hawkes, Eliza
Chiattone, Carlos S.
Cavallo, Federica
Cabras, Giuseppina
Alvarez, Isabel
Fabbri, Alberto
Re, Alessandro
Puccini, Benedetta
Barraclough, Allison
Delamain, Marcia Torresan
Ferrero, Simone
Usai, Sara Veronica
Ferrari, Angela
Cencini, Emanuele
Pennese, Elsa
Zilioli, Vittorio Ruggero
Marino, Dario
Balzarotti, Monica
Cox, Maria Christina
Zanni, Manuela
Di Rocco, Alice
Lleshi, Arben
Botto, Barbara
Hohaus, Stefan
Merli, Michele
Sartori, Roberto
Gini, Guido
Nassi, Luca
Musuraca, Gerardo
Tani, Monica
Bottelli, Chiara
Kovalchuk, Sofia
Re, Francesca
Flenghi, Leonardo
Molinari, Annalia
Tarantini, Giuseppe
Chimienti, Emanuela
Marcheselli, Luigi
Mammi, Caterina
Spina, Michele
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (11) : 1214 - +
[5] Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review by the Fondazione Italiana Linfomi
Nassi, Luca
De Sanctis, Vitaliana
Loseto, Giacomo
Gerardi, Chiara
Allocati, Eleonora
Ciavarella, Sabino
Minoia, Carla
Guarini, Attilio
Bari, Alessia
CANCERS, 2022, 14 (03)
[6] Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data
Furqan, Fateeha
Hamadani, Mehdi
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
[7] Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial
Zinzani, Pier Luigi
Pellegrini, Cinzia
Gandolfi, Letizia
Stefoni, Vittorio
Quirini, Federica
Derenzini, Enrico
Broccoli, Alessandro
Argnani, Lisa
Pileri, Stefano
Baccarani, Michele
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (06) : 462 - 466
[8] Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
Lee, Yong-Pyo
Hong, Jung Yong
Yoon, Sang Eun
Cho, Junhun
Shim, Joon-Ho
Bang, Yeonghak
Kim, Won Seog
Kim, Seok Jin
CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 4241 - 4250
[9] The Impact of Healthy Lifestyles on Late Sequelae in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors. A Systematic Review by the Fondazione Italiana Linfomi
Minoia, Carla
Gerardi, Chiara
Allocati, Eleonora
Daniele, Antonella
De Sanctis, Vitaliana
Bari, Alessia
Guarini, Attilio
CANCERS, 2021, 13 (13)
[10] Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
Appio, Lorena
Landoni, Carlo
La Targia, Maria
Bertolli, Vanda
Chiarucci, Martina
Crovetti, Giovanni
Vassenna, Elisabetta
Serio, Giovanni
Bregni, Marco
CHEMOTHERAPY, 2017, 62 (03) : 187 - 191

← 1 2 3 4 5 →